FORM PTO-1449	ATTY. DOCKET NO. 30727.0013.CIP1	SERIAL NO. 09/518,501
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT: METABASIS THERAPEUTICS, INC.	
	FILING DATE: March 5, 1999	GROUP: 1614

OIPE JUN 11 2001 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA	3,018,302	01.23.62	Bielefeld, et al.			
	AB	5,157,027	10/20 92	Biller, et al.			
	AC	5,658,889	8/19/97	Gruber, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES	TRANSLATION NO
	AD	0 002 062 A	30.05.79	EP (Abstract)				
	AE	0 072 531 A	23.02.83	EP (Abstract)				
	AF	0 158 057 A	16.10.85	EP (Abstract)				
	AG	0 180 276	28.12.88	EP				
	AH	0 261 283	22.09.86	EP				
	AI	0 161 955 A	21.11.85	EPO				
	AJ	0 338 372 A	25.10.89	EPO				
	AK	0 353 692 A	07.02.90	EPO				
	AL	0 481 214 A	22.04.92	EPO				
	AM	492 738 A	30.06.70	CH				
	AN	16 93 219 A	17.09.70	DE (Abstract)				

EXAMINER:	DATE CONSIDERED: 7/9/01

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

FORM PTO-1449	ATTY. DOCKET NO. 30727.0013.CIP1	SERIAL NO. 09/518,501
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT: METABASIS THERAPEUTICS, INC.	
	FILING DATE: March 5, 1999	GROUP: 1614

OIPE JC1 JUN 11 2002 PATENT & TRADEMARK OFFICE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES	TRANSLATION NO
	AO	35 12 781 A1	10.04.85	DE (and English language U.S. Patent No. 4,952,740)				
	AP	96/01267 A	18.01.96	WO				
	AQ	97/03679 A	06.02.97	WO				
	AR	98/09668 A	12.03.98	WO				
	AS	98/39342	11.09.98	WO				
	AT	98/39343	11.09.98	WO				
	AU	98/39344	11.09.98	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	AV	"Patent Abstracts of Japan," Vol. 1998, No. 1, 30 January 1998 & JP 09 241284 A (Yamishata Koji; Nippon Soda Co. Ltd), 16 September 1997
	AW	DeLombaert, et al., "*N*-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endoprptidase (NEP, EC 3.4.24.11) Inhibitors, J. Med. Chem. 37: 498-511 (1994)
	AX	Edmunson, et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dioxaphosphorinane Series. X-Ray Molecular Structure of *cis*-2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," J. Chem. Res. Synop., 5: 122-123 (1989)
	AY	Farquhar, et al., "5'-'4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorin an –2-y]l-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)'" J. Med. Chem. 38:488-495 (1995)
	AZ	Farquhar, et al., "Biologically Reversible Phosphate-Protective Groups," J. Pharm. Sci. 72(3): 324 (1983)

all articles

EXAMINER: Examiner	DATE CONSIDERED: 2/6/02

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

FORM PTO-1449	ATTY. DOCKET NO.	SERIAL NO.
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	30727.0013.CIP1	09/518,501
(Use several sheets if necessary)	APPLICANT: METABASIS THERAPEUTICS, INC.	
	FILING DATE: March 5, 1999	GROUP: 1614

OIPE JC186 JUN 11 2001 PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	BA	Farquhar, et al., "Synthesis and Biological Evaluation of 9-[5'-(2-Oxo-1,3,2-oxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine and 9-[5'-(2-Oxo-1,3,2-dioxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine: Potential Neutral Precursors of 9-[ß-D-Arabinofuranosyl]adenine 5'-Monophosphate," J. Med. Chem. 28: 1358-1361 (1985)
	BB	Farquhar, et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5-Fluoro-2'-deoxyuridine 5'-Phosphate," J. Med. Chem. 26: 1153-1158 (1983)
	BC	Freed, et al., "Evidence For Acyloxymethyl Esters of Pyrimidine 5'-Deoxyribonucleotides as Extracellular Sources of Active 5'-Deoxyribonucleotides in Cultured Cells," Biochem. Pharmac. 38: 3193-3198 (1989)
	BD	Hillers, et al., "Analogs of pyrimidinemono-and polynucleotides. IV. Phosphates of 1-(1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-propyl) uracil." Khim Geterotski Soedin 5:678-683 (1978). Chem Abst. v 89 no 17; abst no 146864a
	BE	Hunston, et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," J. Med. Chem. 27: 440-444 (1984)
	BF	Kryuchkov, et al., Izv. Akad. Nauk SSSR, Ser. Khim. 6: 1201-1248 (1987)
	BG	Lok, et al., "Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection," J. Antimicrob. Chemotherap. 14: 93-99 (1984)
	BH	Ludeman, et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenyl ketophos phamide" and Similar Compounds Related to the Cyclophosphamide Metabolyte Aldophosphamide," J. Med Chem. 29, 716-727 (1986)
	BI	Meier, et al., "Cyclic Saligenyl Phosphotreisters of 2', 3'-Dideoxy-2', 3'-didehydrothymidine (d4T) – A New Pro-Nucleotide Approach," Bioorg. Med. Chem. Lett. 7: 99-104 (1977)
	BJ	Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyclic 3', 5'-Phosphates as Prodrugs of Thioinosinic Acid," J. Med. Chem. 22: 811-815 (1979)
	BK	Neidlein, et al., "Mild Preparation of 1-Benzyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Deisters and Cyclic Monoester Amides," Heterocycles 35: 1185-1203 (1993)

EXAMINER: Examiner	DATE CONSIDERED: 7/6/02

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

FORM PTO-1449	ATTY. DOCKET NO.	SERIAL NO.
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	30727.0013.CIP1	09/518,501
(Use several sheets if necessary)	APPLICANT: METABASIS THERAPEUTICS, INC.	
	FILING DATE: March 5, 1999	GROUP: 1614

OIPE JC16 JUL 11 2001 PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	BL	Nifant'ev, et al., "1,3,2, - Diazaphodsphorinanes", Zh. Obshch. Khim., Vol. 49, No. 1, 1979, Pages 64-74 (and English version as translated in corresponding English language publication)
	BM	Nifantyev, et al.,"Synthesis and Structure of Some Stable Phospholane-Phospholanes," Phos. Sulfur & Silicon 113, 1-13 (1996)
	BN	Predvoditelev D. , et al., "Glycero-2-hydroxymethylene phosphates" Journal of Organic Chemistry of the USSR (English Translation 13:1489-1492 (1977))
	BO	Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" Journal of Organic Chemistry of the USSR (English Translation 17:1156-1165 (1981)
	BP	Shaw & Cundy, "Biological Screens of PMEA Prodrugs," Pharm. Res. 10 (Suppl) S24 (1993)
	BQ	Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," Bull. Inst. Chem. Acad. Sin. 41: 9-16 (1994)
	BR	Starrett, et al., "Synthesis, Oral Bioavailability Determination, and *in Vitro* Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," J. Med. Chem. 37: 1957-1864 (1994)
	BS	Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Comound Active against Hepatitis B Virus," Antimicrob. Agents Chemoth. 43, 190-193 (1999)
	BT	Zon, et al., "4 Cyclophosphamide Analogues," Prog. Med. Chem. 19: 205-246 (1982)

EXAMINER: Examiner	DATE CONSIDERED: 7/9/02
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant	

#16

Please type a plus sign (+) inside this box →

OIPE JC53 FEB 25 2002 PATENT & TRADEMARK

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	09/518,501
Filing Date	March 3, 2000
First Named Inventor	Erion
Group Art Unit	1624
Examiner Name	T. McKenzie
Attorney Docket Number	030727.0013.CIP1

RECEIVED
MAR 07 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document: Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
JW	AA	Coppi, et al., "Lewis Acid Mediated Condensation of Alkenols and Aldehydes. A Selective Synthesis of Tetrahydropyrans and Oxepanes," J. Org. Chem., Vol. 53, No. 4, 911-913 (1988)	
	AB	Lohr et al., "Targeted chemotherapy by intratumor injection of encapsulated cells engineered to produce CYP2B1, and ifosfamide activating cytochrome P450," Gene Therapy, 5, 1070-1078 (1988).	
	AC	Bijsterbosch, et al., "Disposition of the Acyclic Nucleoside Phsophonate (S)-9-(3-Hydroxy-2-Phosphonylmethoxypropyl)Adenine," Antimicrobial Agents and Chemotherapy," Vol. 42, p. 1146-1150 (May 1998).	
J	AD	de Waziers, et al., "Cytochrome P 450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues1," The Journal of Pharmacology and Experimental Therapeutics, Vol. 253, No.1, p. 387-394 (1989).	

Examiner Signature	T McKenzie	Date Considered	2/12/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation to not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JC53
FEB 25 2002
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box

PTO/SB/08A (09-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	09/516,501
Filing Date	March 5, 1999
First Named Inventor	Erion
Group Art Unit	1624
Examiner Name	T. McKenzie
Attorney Docket Number	030727.0013.CIP1

RECEIVED
MAR 07 2002
TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
TM	AE	He, et al., "Inactivation of Cytochrome P450 3A4 by Bergamottin a Component of Grapefruit Juice," Chem. Res. Toxicol, Vol. 11, No. 4, p. 252-259 (1998).	
gv	AF	Jounaidi et al., "Retroviral Transfer of Human Cytochrome P450 Genes for Oxazaphosphorine-based Cancer Gene Therapy," Cancer Research, Vol. 58, p. 4391- 4401 (Oct. 1, 1998).	

Examiner Signature		Date Considered	2/13/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FORM PTO-1449	ATTY. DOCKET NO. 30727.001[redacted]IP1	SERIAL NO. 09/518,501
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT #11 (Use several sheets if necessary)	APPLICANT: METABASIS THERAPEUTICS, INC.	
	FILING DATE: March 5, 1999	GROUP: 1[redacted]

OIPE JC53 FEB 25 2002 PATENT & TRADEMARK OFFICE

RECEIVED MAR 07 2002 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
TCM	AA	3,018,302	01/23/62	Bielefeld, et al.	260	46	—
TCM	AB	5,157,027	10/20/92	Biller, et al.	514	167	—
TCM	AC	5,658,889	8/19/97	Gruber, et al.	514	43	—

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES	TRANSLATION NO
TCM	AD	0 002 062 A1	30.05.79	EP ~~(and English language Abstract)~~				
TCM	AE	0 072 531 A1	23.02.83	EP ~~(and English language Abstract)~~				
TCM	AF	0 158 057 A	16.10.85	EP (U.K. English language translation)				
	AG	0 180 276 A1	28.12.88	EP				
	AH	0 261 283 A1	22.09.86	EP				
	AI	0 161 955 A1	21.11.85	EPO				
	AJ	0 338 372 A2	25.10.89	EPO				
	AK	0 353 692 A2	07.02.90	EPO				
	AL	0 481 214 B1	22.04.92	EPO				
	AM	492 738	30.06.70	CH (and English language Abstract)				
	AN	987,378	17.09.70	UK				

EXAMINER: [signature]	DATE CONSIDERED: 7/8/02

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

FORM PTO-1449	ATTY. DOCKET NO.	SERIAL NO.
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	30727.001CIP1	09/518,501
(Use several sheets if necessary)	APPLICANT: METABASIS THERAPEUTICS, INC.	
	FILING DATE: March 5, 1999	GROUP: 1614

RECEIVED
MAR 2000
TECH CENTER 1600/2900

FEB 25 2000
PATENT & TRADEMARK OFFICE

FOREIGN PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES	TRANSLATION NO	
	AO	35 12 781 A1	10.04.85	DE (and English language U.S. Patent No. 4,952,740)					
	AP	96/01267	18.01.96	WO					
	AQ	97/03679	06.02.97	WO					
	AR	98/09668	12.03.98	WO					
	AS	98/39342	11.09.98	WO					
	AT	98/39343	11.09.98	WO					
	AU	98/39344	11.09.98	WO					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	AV	"Patent Abstracts of Japan," Vol. 1998, No. 1, 30 January 1998 & JP 09241284 A (Yamishata Koji, et al.; Nippon Soda Co. Ltd), 16 September 1997
	AW	DeLombaert, et al., "*N*-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endoprptidase (NEP, EC 3.4.24.11) Inhibitors, J. Med. Chem. 37: 498-511 (1994)
	AX	Edmunson, et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dioxaphosphorinane Series. X-Ray Molecular Structure of *cis*-2-Benzylamino-4-phenyl-1,3,2-dioxaphosphorinane 2-Oxide," J. Chem. Res. Synop., 5: 122-123 (1989)
	AY	Farquhar, et al., "5'-'4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorin an –2-y]l-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)'" J. Med. Chem. 38:488-495 (1995)
	AZ	Farquhar, et al., "Biologically Reversible Phosphate-Protective Groups," J. Pharm. Sci. 72(3): 324-325 (1983)

EXAMINER: Examiner	DATE CONSIDERED: 7/9/02

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

FORM PTO-1449	ATTY. DOCKET NO. 30727.001 IP1	SERIAL NO. 09/518,501
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT: METABASIS THERAPEUTICS	
	FILING DATE: March 5, 1999	GROUP: 1614

OIPE MAR 2 5 2002 PATENT & TRADEMARK OFFICE

RECEIVED MAR 07 2002 TECH CENTER 1600/2900

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	BA	Farquhar, et al., "Synthesis and Biological Evaluation of 9-[5'-(2-Oxo-1,3,2-oxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine and 9-[5'-(2-Oxo-1,3,2-dioxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine: Potential Neutral Precursors of 9-[ß-D-Arabinofuranosyl]adenine 5'-Monophosphate," J. Med. Chem. 28: 1358-1361 (1985)
	BB	Farquhar, et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5-Fluoro-2'-deoxyuridine 5'-Phosphate," J. Med. Chem. 26: 1153-1158 (1983)
	BC	Freed, et al., "Evidence For Acyloxymethyl Esters of Pyrimidine 5'-Deoxyribonucleotides as Extracellular Sources of Active 5'-Deoxyribonucleotides in Cultured Cells," Biochem. Pharmac. 38: 3193-3198 (1989)
	BD	Hillers, et al., "Analogs of pyrimidinemono-and polynucleotides. IV. Phosphates of 1-(1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-propyl) uracil." Khim Geterotski Soedin 5:678-683 (1978). Chem Abst. v 89 no 17; abst no 146864u
	BE	Hunston, et al., "Synthesis and Biological Properties of Some Cyclic Phosphotriesters Derived from 2'-Deoxy-5-fluorouridine," J. Med. Chem. 27: 440-444 (1984)
	BF	Kryuchkov, et al., Izv. Akad. Nauk SSSR, Ser. Khim. 6: 1201-1248 (1987)
	BG	Lok, et al., "Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection," J. Antimicrob. Chemotherap. 14: 93-99 (1984)
	BH	Ludeman, et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenyl ketophos phamide" and Similar Compounds Related to the Cyclophosphamide Metabolyte Aldophosphamide," J. Med Chem. 29, 716-727 (1986)
	BI	Meier, et al., "Cyclic Saligenyl Phosphotreisters of 2', 3'-Dideoxy-2', 3'-didehydrothymidine (d4T) – A New Pro-Nucleotide Approach," Bioorg. Med. Chem. Lett. 7: 99-104 (1997)
	BJ	Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyclic 3', 5'-Phosphates as Prodrugs of Thioinosinic Acid," J. Med. Chem. 22: 811-815 (1979)
✓	BK	Neidlein, et al., "Mild Preparation of 1-Benzyloxyiminoalkylphosphonic Dichlorides: Application to the Synthesis of Cyclic Phosphonic Deisters and Cyclic Monoester Amides," Heterocycles 35: 1185-1203 (1993)

EXAMINER: Examiner	DATE CONSIDERED: 7/9/02

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

FORM PTO-1449	ATTY. DOCKET NO. 30727.001[redacted]IP1	SERIAL NO. 09/518,501
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: METABASIS THERAPEUTICS, INC.	
(Use several sheets if necessary)	FILING DATE: March 5, 1999	GROUP: 1614

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
FEB 25 2002
PATENT & TRADEMARK OFFICE
RECEIVED
MAR 07 2002
TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	BL	Nifant'ev, et al., "1,3,2, - Diazaphodsphorinanes", Zh. Obshch. Khim., Vol. 49, 1979, Pages 53-61.
	BM	Nifantyev, et al.,"Synthesis and Structure of Some Stable Phospholane-Phospholanes," Phos. Sulfur & Silicon 113, 1-13 (1996)
	BN	Predvoditelev D. , et al., "Glycero-2-hydroxymethylene phosphates" Journal of Organic Chemistry of the USSR (English Translation 13:1489-1492 (1977))
	BO	Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" Journal of Organic Chemistry of the USSR (English Translation 17:1156-1165 (1981)
	BP	Shaw & Cundy, "Biological Screens of PMEA Prodrugs," Pharm. Res. 10 (Suppl) S-294 (1993)
	BQ	Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," Bull. Inst. Chem. Acad. Sin, 41: 9-16 (1994)
	BR	Starrett, et al., "Synthesis, Oral Bioavailability Determination, and *in Vitro* Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," J. Med. Chem. 37: 1857-1864 (1994)
	BS	Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Comound Active against Hepatitis B Virus," Antimicrob. Agents Chemoth. 43, 190-193 (1999)
	BT	Zon, et al., "4 Cyclophosphamide Analogues," Prog. Med. Chem. 19: 205-246 (1982)

EXAMINER: Examiner	DATE CONSIDERED: 7/9/02

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

OIPE
DEC 0 8 2003
PATENT & TRADEMARK OFFICE

PTO/SB/08A (03-03)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	09/518,501
Filing Date	March 3, 2000
First Named Inventor	Erion et al.
Group Art Unit	1624
Examiner Name	McKenzie, T.
Attorney Docket Number	45199.00013.RCE (CIP1)

RECEIVED
DEC 1 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
TM		6,054,587		Reddy et al.	04/25/00	
		6,110,903		Kasibhatla et al.	08/29/00	
		6,284,748		Dang et al.	09/04/01	
		6,294,672		Reddy et al.	09/25/01	
		6,312,662		Erion et al.	11/06/01	
		6,399,782		Kasibhatla et al.	06/04/02	
V		6,489,476		Dang et al.	12/03/02	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]

Examiner Signature		Date Considered	4/16/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

OIPE JC1
DEC 21 2000
PATENT & TRADEMARK OFFICE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	09/516,501
Filing Date	March 3, 2000
First Named Inventor	Erion et al.
Group Art Unit	1624
Examiner Name	T. McKenzie
Attorney Docket Number	45198.00013.RCE

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document: Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		FARQUHAR et al., "Synthesis and Antitumor Evaluation of Bis[pivaloyloxy)methyl] 2'-Deoxy-5-fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).	
		LEFEBVRE, et al., Mononucleotide Phosphotriester Derivatives with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3'-Azido-2',3'-dideoxythymidine 5'-Monophosphate," J. Med. Chem., 38:3941-3950 (1995).	

Examiner Signature		Date Considered	4/16/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

OIPE
FEB 27 2004
PATENT & TRADEMARK OFFICE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete If Known	
Application Number	09/518,501
Filing Date	March 3, 2000
First Named Inventor	Erion et al.
Group Art Unit	1624
Examiner Name	T. McKenzie
Attorney Docket Number	032465.00013.RCE (CIP1)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document: Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		Beaucage and Iyer, "The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications," Tetrahedron, 49(28):6123-6194 (1993).	
		Borch and Millard, "The Mechanism of Activation of 4-Hydroxycyclophosphamide," J. Med. Chem., 30:427-431 (1987).	
		Cooper et al., "Use of Carbohydrate Derivatives for Studies of Phosphorus Stereo-chemistry. Part II. Synthesis and Configurational Assignments of 1,-3,2-Oxathiaphosphorinan-2-ones and 1,3,2-Dioxaphosphorinan-2-thiones," J. Chem. Soc., Perk. Trans. 1, (10):1049-1052 (1974).	
		De Clercq et al., "A Novel Selective Broad-spectrum Anti-DNA Virus Agent," Nature, 323:464-467 (1986).	
		Farquhar et al., "Synthesis and Antitumor Evaluation of Bis[(pivaloyloxy)methyl] 2'-Deoxy-5-fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).	

Examiner Signature		Date Considered	4/16/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

O I P E
FEB 17 2004
PATENT & TRADEMARK OFFICE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	09/518,501
Filing Date	March 3, 2000
First Named Inventor	Erion et al.
Group Art Unit	1626
Examiner Name	T. McKenzie
Attorney Docket Number	032465.00013.RCE (CIP1)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		Friis and Bundgaard, "Prodrugs of Phosphates and Phosphonates: Novel Lipophilic α-acyloxyalkyl Ester Derivatives of Phosphate- or Phosphonate Containing Drugs Masking the Negative Charges of these Groups," Euro. J. Pharm. Sci., 4:49-59 (1996).	
		Harada et al., "Resoluation of 1,3-alkanediols Via Chiral Spiroketals Derived from l-Menthone," Tetrahedron, 28(41):4843-4846 (1987).	
		Khorana et al., "Cyclic Phosphates. III. Some General Observations on the Formation and Properties of Five-, Six- and Seven-membered Cyclic Phophate Esters," JACS, 79:430-436 (1957).	
		Korba et al., "Liver-targeted Antiviral Nucleosides: Enhanced Antiviral Activity of Phosphatidyl-dideoxyguanosine Versus Dideoxyguanosine in Woodchuck Hepatitis Virus Infection *In Vivo*," Hepatology, 23(5):958-963 (1996).	
		Lefebvre et al., "Mononucleoside Phosphotriester Derivatives with *S*-acyl-2-thioethyl Bioreversible Phosphate-protecting Groups: Intracellular Delivery of 3'azido-2',3'dideoxythymidine 5'-monophosphate," J. Med. Chem., 38:3941-3950 (1995).	
		Ludeman et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenylketophosphamide" and Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," J. Med. Chem., 29:716-727 (1986).	
		McGuigan et al., "Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT," J. Med. Chem., 36:1048-1052 (1993).	
		Mosbo and Verkade, "Dipole Moment, Nuclear Magnetic Resonance, and Infrared Studies of Phosphorus Configurations and Equilibria in 2-R-2-Oxo-1,3,2-dioxaphosphorinanes," J. Org. Chem., 42(9):1549-1555 (1977).	
		Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," J. Am. Chem. Soc., 112:6936-3942 (1990).	
		Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Ketoalkyl Diisopinocampheylborinate Intermediates," Tetrahedron, 38(3):761-764 (1997).	

Examiner Signature		Date Considered	4/16/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

OIPE JC64 FEB 2 2004 PATENT & TRADEMARK OFFICE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete If Known	
Application Number	09/518,501
Filing Date	March 3, 2000
First Named Inventor	Erion et al.
Group Art Unit	1624
Examiner Name	T. McKenzie
Attorney Docket Number	032465.00013.RCE (CIP1)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
		Starrett, Jr. et al., "Synthesis, Oral Bioavailability Determination, and *in Vitro* Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)," J. Med. Chem., 37:1857-1864 (1994).	
		Thomson et al., "Synthesis, Bioactivation and Anti-HIV Activity of the Bis(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Esters of the 5'-monophosphate of AZT," J. Chem. Soc., Perk. Trans. 1, (11):1239-1245 (1993).	
		Weber and Waxman, "Activation of the Anti-cancer Drug Ifosphamide by Rat Liver Microsomal P450 Enzymes," Biochem. Pharm., 45(8):1685-1694 (1993).	
		Zon et al., "NMR Spectroscopic Studies of Intermediary Metabolites of Cyclophosphamide. A Comprehensive Kinetic Analysis of the Interconversion of *cis*- and *trans*-4-Hydroxycyclophosphamide with Aldophosphamide and Concomitant Partitioning of Aldophosphamide Between Irreversible Fragmentation and Reversible Conjugation Pathways," J. Med. Chem. 27:466-485 (1984).	

Examiner Signature	Tom McKenzie	Date Considered	4/16/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

OIPE JUN 2 8 2005 PATENT & TRADEMARK OFFICE

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	APPLICATION NO.
2358.0010002/RWE/CJW	09/518,501
FIRST NAMED INVENTOR: Erlon *et al.*	
FILING DATE: March 3, 2000	ART UNIT: 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	3,404,178	10/01/1968	Roy, C.H.			10/07/1965
	AB1	4,621,077	11/04/1986	Rosini *et al.*			06/08/1984
	AC1	4,659,825	04/21/1987	Holy *et al.*			01/06/1984
	AD1	4,705,651	11/10/1987	Staibano			10/11/1985
	AE1	4,724,232	02/09/1988	Rideout *et al.*			09/17/1985
	AF1	4,724,233	02/09/1988	De Clercq *et al.*			04/21/1986
	AG1	4,777,163	10/11/1988	Bosies *et al.*			07/24/1987
	AH1	4,808,716	02/28/1989	Holy *et al.*			04/25/1986
	AI1	4,861,759	08/29/1989	Mitsuya *et al.*			08/11/1987
	AJ1	4,879,277	11/07/1989	Mitsuya *et al.*			08/11/1987
	AK1	4,882,142	11/21/1989	Simon *et al.*			12/19/1988

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER: Dan McKenzie

DATE CONSIDERED: 9/16/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIPE
JUN 2 8 2005
PATENT & TRADEMARK OFFICE

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 2358.0010002/RWE/CJW	APPLICATION NO. 09/518,501
FIRST NAMED INVENTOR Erion *et al.*	
FILING DATE March 3, 2000	ART UNIT 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2	4,898,724	02/06/1990	Simon *et al.*			05/14/1987
	AB2	4,939,130	07/03/1990	Jaeggi *et al.*			02/27/1989
	AC2	5,034,394	07/23/1991	Daluge			12/22/1989
	AD2	5,047,533	09/10/1991	Reist *et al.*			01/22/1990
	AE2	5,089,500	02/18/1992	Daluge			05/08/1991
	AF2	5,153,183	10/06/1992	Kawabe *et al.*			05/06/1991
	AG2	5,210,085	05/11/1993	Liotta *et al.*			02/22/1991
	AH2	5,240,946	08/31/1993	Kinney *et al.*			04/29/1992
	AI2	5,246,937	09/21/1993	Harnden *et al.*			01/22/1992
	AJ2	5,366,965	11/22/1994	Strein			01/29/1993
	AK2	5,480,875	01/02/1996	Isomura *et al.*			371 Date: 12/21/1994

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER	DATE CONSIDERED
	9/16/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIPE
JUN 2 8 2005
PATENT & TRADEMARK OFFICE

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	APPLICATION NO.
2358.0010002/RWE/CJW	09/518,501
FIRST NAMED INVENTOR: Erion *et al.*	
FILING DATE: March 3, 2000	ART UNIT: 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA3	5,532,225	07/02/1996	Reist *et al.*			07/31/1992
	AB3	5,583,122	12/10/1996	Benedict *et al.*			12/06/1985
	AC3	5,663,159	09/02/1997	Starrett, Jr. *et al.*			10/11/1994
	AD3	5,681,590	10/28/1997	Bechard *et al.*			371 Date: 07/26/1995
	AE3	5,721,219	02/24/1998	Ingall *et al.*			08/09/1995
	AF3	5,814,639	09/29/1998	Liotta *et al.*			02/16/1993
	AG3	5,840,716	11/24/1998	Ubasawa *et al.*			01/17/1997
	AH3	5,869,467	02/09/1999	Holy *et al.*			03/28/1995
	AI3	5,914,331	06/22/1999	Liotta *et al.*			06/07/1995
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER	DATE CONSIDERED
	5/11/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIPE IAP34
DEC 20 2005
PATENT & TRADEMARK OFFICE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 1 of 12		
	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant	Relevant Pages
TM	A1	3,796,700	03/12/1974	Yoshioka et al.	all
	A2	4,255,566	03/10/1981	Carrico et al.	all
	A3	4,318,982	03/09/1982	Hornby et al.	all
	A4	4,340,668	07/20/1982	Hornby et al.	all
	A5	4,376,165	03/08/1983	Hornby et al.	all
	A6	4,447,529	05/08/1984	Greenquist et al.	all
	A7	4,804,655	02/14/1989	Müller et al.	all
	A8	5,204,355	04/20/1993	Zsadon et al.	all
	A9	5,212,304	05/18/1993	Fung et al.	all
	A10	5,258,538	11/02/1993	Fung et al.	all
	A11	6,117,873	09/12/2000	Acklin et al.	all
	A12	6,752,981 B1	06/22/2004	Erion et al.	all
✓	A13	6,756,360 B1	06/29/2004	Erion et al.	all

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document (Cty code-number-kind)	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant	Relevant Pages	T[1]
TM	B1	WO 91/19721 A1	12/26/1991	Glazier, Arnold	all	
TM	B2	WO 97/22614 A1	06/26/1997	Chiroscience Ltd.	all	
TM	B3	WO 01/39724 A2	06/07/2001	Regents of Univ. of Calif.	all	
					all	

Examiner Signature	Tom McKenzie	Date Considered	3/11/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant is to place a check mark here if English language translation is attached.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 2 of 12		
	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Description	T[1]
TCM	C1	ALARCON, R.A., "Studies on the In Vivo Formation of Acrolein: 3-Hydroxy-propylmercapturic Acid as an Index of Cyclophosphamide (NSC-26271) Activation," *Cancer Treatment Reports* 60(4), 327-335, U.S. National Cancer Institute (1976).	
	C2	ALEXANDER, P. et al., "Preparation of 9-(2-Phosphonomethoxyethyl) Adenine Esters as Potential Prodrugs," *Collect. Czech. Chem. Commun.* 59, 1853-1869, Nakladatelstvi Ceskoslovenski Akademie Ved. (1994).	
	C3	AMIN, D. et al., "1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic Acid as a Potent Inhibitor of Squalene Synthase," *Arzneim.-Forsch/Drug Res.* 46(8), 759-762, Editio Cantor (1996).	
	C4	ANDERSON, L.W. et al., "Cyclophosphamide and 4-Hydroxycyclophosphamide/ Aldophosphamide Kinetics in Patients Receiving High-Dose Cyclophosphamide Chemotherapy," *Clinical Cancer Research* 2, 1481-1487, American Association for Cancer Research (1996).	
	C5	ANNAERT, P. et al., "Transport, Uptake, and Metabolism of the Bis(pivaloyloxymethyl)-Ester Prodrug of 9-(2-Phosphonylmethoxyethyl) Adenine in an In Vitro Cell Culture System of the Intestinal Mucosa (Caco-2)," *Pharm. Res.* 14(4), 492-496, Plenum Publishing Corporation (1997).	
	C6	ATIQ, O.T. et al., "Treatment of Unresectable Primary Liver Cancer with Intrahepatic Fluorodeoxyuridine and Mitomycin C Through an Implantable Pump," *Cancer* 69(4), 920-924, American Cancer Society (1992).	
	C7	AUBERSON, Y.P. et al., "N-Phosphonoalkyl-5-Aminomethylquinoxaline-2,3-Diones: *In Vivo* Active AMPA and NMDA-(Glycine) Antagonists," *Bioorg. Med. Chem. Lett.* 9, 249-254, Elsevier Science Ltd. (January 1999).	
	C8	BAKER, M.A. et al., "Microtiter Plate Assay for the Measurement of Glutathione and Glutathione Disulfide in Large Numbers of Biological Samples," *Anal. Biochem.* 190, 360-365, Academic Press, Inc. (1990).	
	C9	BALTHAZOR, T.M. et al., "Nickel-Catalyzed Arbuzov Reaction: Mechanistic Observations," *J. Org. Chem.* 45, 5425-5426, American Chemical Society (1980).	
	C10	BEDFORD, S.B. et al., "Synthesis of Water-Soluble Prodrugs of the Cytotoxic Agent Combretastatin A4," *Bioorg. Med. Chem. Lett.* 6(2), 157-160, Elsevier Science Ltd. (1996).	

Examiner Signature	Tom McKenzie	Date Considered	3/11/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant is to place a check mark here if English language translation is attached.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 3 of 12		
	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Description	T[1]
TCM	C11	Beilstein Registry Number 3635189, *Beilstein Institut zur Foerderung der Chemischen Wissenschaften* (1991).	
	C12	BENTRUDE, W.G. et al., "Stereo- and Regiochemistries of the Oxidations of 2-Methoxy-5-*tert*-butyl-1,3,2-dioxaphosphorinanes and the Cyclic Methyl 3'5'-Phosphite of Thymidine by H_2O/I_2 and O_2/AIBN to P-Chiral Phosphates. ^{17}O NMR Assignment of Phosphorus Configuration to the Diasteromeric Thymidine Cyclic Methyl 3'5'-Monophosphates," *J. Am. Chem. Soc.* 111, 3981-3987, American Chemical Society (1989).	
	C13	BERRY, M.N. et al., "High-Yield Preparation of Isolated Rat Liver Parenchymal Cells," *J. of Cell Biology* 43, 506-520, Rockefeller University Press (1969).	
	C14	BESPALOV, A. et al., "Prolongation of Morphine Analgesia by Competitive NMDA Receptor Antagonist D-CPPene (SDZ EAA 494) in Rats," *Eur. J. Pharmacol.* 351, 299-305, Elsevier Science B.V. (June 1998).	
	C15	BIJSTERBOSCH, M.K. et al., "Disposition of the Acyclic Nucleoside Phosphonate (*S*)-9-(3-Hydroxy-2-Phosphonylmethoxyproply)Adenine," *Antimicrobial Agents and Chemotherapy* 42, 1146-1150, American Society for Microbiology (May 1998).	
	C16	BIRD, J. et al., "Synthesis of Novel *N*-Phosphonoalkyl Dipeptide Inhibitors of Human Collagenase," *J. Med. Chem.* 37, 158-169, American Chemical Society (1994).	
	C17	BODDY, A.V. et al., "Individual Variation in the Activation and Inactivation of Metabolic Pathways of Cyclophosphamide," *J. National Cancer Institute* 84(22), 744-748, Oxford University Press (1992).	
	C18	BORCH, R.F. et al., "Synthesis, Activation and Cytotoxicity of Aldophosphamide Analogues," *J. Med. Chem.* 34, 3052-3058, American Chemical Society (1991).	
	C19	BORCH, R.F. et al., "Synthesis and Antitumor Properties of Activated Cyclophosphamide Analogues," *J. Med. Chem.* 34, 3044-3052, American Chemical Society (1991).	
	C20	BOYD, V.L. et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 3. Preparation, Molecular Structure Determination, and Anticancer Screening of Racemic *cis*- and *trans*-4-Phenylcyclophosphamide," *J. Med. Chem.* 23, 372-375, American Chemical Society (1980).	
	C21	BRAIN, E.G.C. et al., "Modulation of P450-Dependent Ifosfamide Pharmacokinetics: a Better Understanding of Drug Activation In Vivo," *British J. of Cancer* 77(11), 1768-1776, Cancer Research Campaign (June 1998).	

Examiner Signature	Tom McKenzie	Date Considered	3/11/05

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant is to place a check mark here if English language translation is attached.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 4 of 12		
	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Description	T[1]
TM	C22	BRENNA, O. et al., "Affinity-Chromatography Purification of Alkaline Phosphatase from Calf Intestine," *Biochem. J.* 151, 291-296, Portland Press on behalf of The Biochemical Society (1975).	
	C23	BRILL, T.B. et al., "Arbuzov-like Dealkylation Reactions of Transition-Metal-Phosphite Complexes," *Chem. Rev.* 84, 577-585, American Chemical Society (1984).	
	C24	BROCK, N. et al., "Acrolein, the Causative Factor of Urotoxic Side-effects of Cyclophosphamide, Ifosfamide, Trofosfamide and Sufosfamide" *Arzneimittel Forschung Drug Research* 29(4), 659-661, Editio Cantor (1979).	
	C25	CAMPAGNE, J.-M. et al., "Synthesis of Mixed Phosphonate Diester Analogues of Dipeptides using BOP or PyBOP Reagents," *Tetrahedron Lett.* 34(42), 6743-6744, Pergamon Press Ltd. (1993).	
	C26	CAMPBELL, D.A., "The Synthesis of Phosphonate Esters, an Extension of the Mitsunobu Reaction," *J. Org. Chem.* 57, 6331-6335, American Chemical Society (1992).	
	C27	CASARA, P.J. et al., "Synthesis of Acid Stable 5'-O-Fluoromethyl Phosphonates of Nucleosides. Evaluation as Inhibitors of Reverse Transcriptase," *Bioorg. Med. Chem. Lett.* 2(2), 145-148, Pergamon Press plc. (1992).	
	C28	CASTEEL, D.A. et al., "Steric and Electronic Effects in the Aryl Phosphate to Arylphosphonate Rearrangement," *Synthesis*, 691-693, Sendai Institute of Heterocyclic Chemistry (1991).	
	C29	CHANG, T.K.H. et al., "Enhanced Cyclophosphamide and Ifosfamide Activation in Primary Human Hepatocyte Cultures: Response to Cytochrome P-450 Inducers and Autoinduction by Oxazaphosphorines," *Cancer Research* 57, 1946-1954, American Association for Cancer Research (1997).	
	C30	CHEN, L. et al., "Intratumoral Activation and Enhanced Chemotherapeutic Effect of Oxazaphosphorines following Cytochrome P-450 Gene Transfer: Development of a Combined Chemotherapy/Cancer Gene Therapy Strategy," *Cancer Research* 55, 581-589, American Association for Cancer Research (1995).	
	C31	CHEN, L. et al., "Sensitization of Human Breast Cancer Cells to Cyclophosphamide and Ifosfamide by Transfer of a Liver Cytochrome P450 Gene," *Cancer Research* 56, 1331-1340, American Association for Cancer Research (1996).	
✓	C32	CLARK, L. et al., "Oxidative Metabolism of Cyclophosphamide: Identification of the Hepatic Monooxygenase Catalysts of Drug Activation," *Cancer Research* 49, 2344-2350 American Association for Cancer Research (1989).	

Examiner Signature	Tom McKenzie	Date Considered	3/11/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant is to place a check mark here if English language translation is attached.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 5 of 12	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Description	T[1]
qm	C33	DAVIS, L. et al., "Effect of *Withania somnifera* on Cyclosphosphamide-induced Urotoxicity," *Cancer Letters* 148, 9-17, Elsevier Science Ireland Ltd. (January 2000).	
	C34	DEARFIELD, K.L. et al., "Analysis of the Genotoxicity of Nine Acrylate/Methacrylate Compounds in L5178Y Mouse Lymphoma Cells," *Mutagenesis* 4, 381-393, IRL Press, Oxford (1989).	
	C35	DELEVE, L.D. et al., "Cellular Target of Cyclophosphamide Toxicity in the Murine Liver: Role of Glutathione and Site of Metabolic Activation," *Hepatology* 24(4), 830-837, American Association for the Study of Liver Diseases (1996).	
	C36	DELOMBAERT, S. et al., "Pharmacological Profile of a Non-Peptidic Dual Inhibitor of Neutral Endopeptidase 24.11 and Endothelin-Converting Enzyme," *Biochem. Biophys. Res. Commun.* 204(1), 407-412, Academic Press, Inc. (1994).	
	C37	DESOS, P. et al., "Structure-Activity Relationships in a Series of 2(1*H*)-Quinolones Bearing Different Acidic Function in the 3-Position: 6,7-Dichloro-2(1*H*)-oxoquinoline-3-phosphonic Acid, a New Potent and Selective AMPA/Kainate Antagonist with Neuroprotective Properties," *J. Med. Chem.* 39, 197-206, American Chemical Society (1996).	
	C38	DICKSON, J.K. et al., "Orally Active Squalene Synthase Inhibitors: Bis((acyloxy)alkyl) Prodrugs of the α-Phosphonosulfonic Acid Moiety," *J. Med. Chem.* 39, 661-664, American Chemical Society (1996).	
	C39	ENRIQUEZ, P.M. et al., "Conjugation of Adenine Arabinoside 5'-Monophosphate to Arabinogalactan: Synthesis, Characterization, and Antiviral Activity," *Bioconjugate Chem.* 6, 195-202, American Chemical Society (1995).	
	C40	ERION, M.D. et al., "Design, Synthesis, and Characterization of a Series of Cytochrome P_{450} 3A-Activated Prodrugs (HepDirect Prodrugs) Useful for Targeting Phosph(on)ate-Based Drugs to the Liver," *J. Am. Chem. Soc.* 126, 5154-5163, American Chemical Society (April 2004).	
	C41	ERION, M.D. et al., "Liver-Targeted Drug Delivery Using HepDirect Prodrugs," *J. of Pharmacology & Experimental Therapeutics* 312(2), 554-560, The American Society for Pharmacology and Experimental Therapeutics (February 2005).	
	C42	FARQUHAR, D. et al., "Biologically-Cleavable Phosphate Protective Groups: 4-Acyloxy-1,3,2-Dioxaphosphorinanes as Neutral Latent Precursors of Dianionic Phosphates," *Tetrahedron Lett.* 36(5), 655-658, Elsevier Science Ltd. (1995).	

Examiner Signature	Tom McKenzie	Date Considered	3/11/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant is to place a check mark here if English language translation is attached.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 6 of 12	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Description	T[1]
	C43	FIUME, L. et al., "Inhibition of Hepatitis B Virus Replication by Vidarbine Monophosphate Conjugated with Lactosaminated Serum Albumin," *The Lancet* 13-15, Lancet Publishing Group (1988).	
	C44	FRAISER, L. et al., "Murine Strain Differences in Metabolism and Bladder Toxicity of Cyclophosphamide," *Toxicology* 75, 257-272, Elsevier Scientific Publishers (1992).	
	C45	GAO, Y. et al., "Asymmetric Synthesis of Both Enantiomers of Tomoxetine and Fluoxetine. Selective Reduction of 2,3-Epoxycinnamyl Alcohol with Red-A1," *J. Org. Chem.* 53, 4081-4084, American Chemical Society (1988).	
	C46	GILARD, V. et al., "Chemical Stability and Fate of the Cytostatic Drug Ifosfamide and Its N-Dechloroethylated Metabolities in Acidic Aqueous Solutions," *J. Med. Chem.* 42, 2542-2560, American Chemical Society (July 1999).	
	C47	GROEN, A.K. et al., "Intracellular Compartmentation and Control of Alanine Metabolism in Rat Liver Parenchymal Cells," *Eur. J. Biochem.* 122, 87-93, FEBS (1982).	
	C48	GUIDA, W.C. et al., "Structure-Based Design of Inhibitors of Purine Nucleoside Phosphorylase. 4. A Study of Phosphate Mimics," *J. Med. Chem.* 37, 1109-1114, American Chemical Society (1994).	
	C49	GURTOO, H.L. et al., "Role of Glutathione in the Metabolism-dependent Toxicity and Chemotherapy of Cyclophosphamide," *Cancer Research* 41, 3584-3591, American Association for Cancer Research (1981).	
	C50	GUSTIN, N.C. et al., "A Rapid, Sensitive Assay for Adenosine Deaminase," *Analytical Biochemistry* 71, 527-532, Academic Press, Inc. (1976).	
	C51	HAYAKAWA, Y. et al., "Benzimidazolium Triflate as an Efficient Promoter for Nucleotide Synthesis via the Phosphoramidite Method," *J. Org. Chem.* 61, 7996-7997, American Chemical Society (1996).	
	C52	HILTON, J., "Role of Aldehyde Dehydrogenase in Cyclophosphamide-resistant L1210 Leukemia," *Cancer Research* 44, 5156-5160, American Association for Cancer Research (1984).	
	C53	HIRAYAMA, N. et al., "Structure and Conformation of a Novel Inhibitor of Angiotensin I Converting Enzyme - a Tripeptide Containing Phosphonic Acid," *Int. J. Pept. Protein Res.* 38, 20-24, Munksgaard International Publishers (1991).	

Examiner Signature		Date Considered	3/11/05

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant is to place a check mark here if English language translation is attached.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 7 of 12	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Description	T[1]
	C54	JOUNAIDI, Y. et al., "Frequent, Moderate-Dose Cyclophosphamide Administration Improves the Efficacy of Cytochrome P-450/Cytochrome P-450 Reductase-based Cancer Gene Therapy," *Cancer Research* 61, 4437-4444, American Association for Cancer Research (June 2001).	
	C55	KACHEL, D.L. et al., "Cyclophosphamide-Induced Lung Toxicity: Mechanism of Endothelial Cell Injury," *J. Pharmacology and Experimental Therapeutics* 268(1), 42-46, The American Society for Pharmacology and Experimental Therapeutics (1994).	
	C56	KEENAN, R.E. et al., "Pathology Reevaluation of the Kociba et al. (1978) Bioassay of 2,3,7,8-TCDD: Implications for Risk Assessment," *J. Tox. Envir. Health* 34, 279-296, Hemisphere Publishing Corporation (1991).	
	C57	KELLEY, J.L. et al., "[[(Guaninylalkyl)phosphinico] methyl] phosphonic Acids. Multisubstrate Analogue Inhibitors of Human Erythrocyte Purine Nucleoside Phosphorylase," *J. Med. Chem.* 38, 1005-1014, American Chemical Society (1995).	
	C58	KHAMNEI, S. et al., "Neighboring Group Catalysis in the Design of Nucleotide Prodrugs," *J. Med. Chem.* 39, 4109-4115, American Chemical Society (1996).	
	C59	KURIYAMA, S. et al., "Transient Cyclophosphamide Treatment Before Intraportal Readministration of an Adenoviral Vector can Induce Re-expression of the Original Gene Construct in Rat Liver," *Gene Therapy* 6, 749-757, Stockton Press (May 1999).	
	C60	KWON, C.-H. et al., "Effects of N-Substitution on the Activation Mechanisms of 4-Hydroxycyclophosphamide Analogues," *J. Med. Chem.* 32, 1491-1496, American Chemical Society (1989).	
	C61	LILO, B. et al., "Synthesis and Configurational Assignment of Bicyclic 'Preactivated' Analogues of Cyclophosphamide," *Tetrahedron Letters* 31(6), 887-890, Pergamon Press plc. (1990).	
	C62	LOW, J.E. et al., "Conversion of 4-Hydroperoxycyclophosphamide and 4-Hydroxycyclophosphamide to Phosphoramide Mustard and Acrolein Mediated by Bifunctional Catalysts," *Cancer Research* 42, 830-837, American Association for Cancer Research (1982).	
	C63	LU, X. et al., "Palladium-Catalyzed Reaction of Aryl Polyfluoroalkanesulfonates with O,O-Dialkyl Phosphonates," *Synthesis* 726-727, Academic Press (1987).	
	C64	LUDEMAN, S.M. et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogs. 1. Benzo Annulated Cyclophosphamide and Related Systems," *J. Med. Chem.* 18(12), 1251-1253, American Chemical Society (1975).	

Examiner Signature		Date Considered	3/11/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant is to place a check mark here if English language translation is attached.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 8 of 12		
	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Description	T[1]
	C65	LUDEMAN, S.M. et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 2. Preparation, Hydrolytic Studies, and Anticancer Screening of 5-Bromocyclophosphamide, 3,5-Dehydrocyclophosphamide, and Related Systems," *J. Med. Chem.* 22(2), 151-158, American Chemical Society (1979).	
	C66	LUDEMAN, S.M. et al., "Synthesis of Reactive Metabolite-Analogues of Cyclophosphamide for Comparisons of NMR Kinetic Parameters and Anticancer Screening Data," *Drugs Exptl. Clin. Res.* XII 6/7, 527-532, Bioscience Ediprint Inc. (1986).	
	C67	MAY-MANKE, A. et al., "Investigation of the Major Human Hepatic Cytochrome P450 Involved in 4-Hydroxylation and N-dechloroethylation of Trofosfamide," *Cancer Chemother. Pharmacol.* 44, 327-334, Springer-Verlag (August 1999).	
	C68	MAYNARD-FAURE, P. et al., "New Strategy for the Diastereoselective Synthesis of Bicyclic 'Pre-activated' Analogues of Cyclophosphamide," *Tetrahedron Letters* 39, 2315-2318, Elsevier Science Ltd. (April 1998).	
	C69	MCGUIGAN, C. et al., "Kinase Bypass: A New Strategy for Anti-HIV Drug Design," *Bioorganic & Medicinal Chemistry Letters* 3(6): 1207-1210, Pergamon Press Ltd. (1993).	
	C70	MEIER, C. et al., "ADA-Bypass by lipophilic *Cyclo*-Sal-ddAMP Pro-Nucleotides A second Example of the Efficiency of the *cyclo*Sat-Concept," *Bioorg. Med. Chem. Lett.* 7(12), 1577-1582, Elsevier Science Ltd. (1997).	
	C71	MEIER, C. et al., "Cyclic Saligenyl Phosphotriesters of 2',3'-Dideoxy-2',3'-didehydrothymidine (d4T) – A New Pro-Nucleotide Approach," *Bioorganic Med. Chem. Lett.* 7(2), 99-104, Elsevier Science Ltd. (1997).	
	C72	MEIJER, D.K.F. et al., "Covalent and Noncovalent Protein Binding of Drugs: Implications for Hepatic Clearance, Storage, and Cell-Specific Drug Delivery," *Pharm. Res.* 6(2), 105-118, Plenum Publishing Corporation (1989).	
	C73	MELVIN, L.S., "An Efficient Synthesis of 2-Hydroxyphenylphosphonates," *Tetrahedron Lett.* 22(35), 3375-3376, Pergamon Press Ltd. (1981).	
	C74	MISIURA, K. et al., "Synthesis and Antitumor Activity of Analogues of Ifosfamide Modified in the N-(2-Chloroethyl) Group," *J. Med. Chem.* 31(1), 226-230, American Chemical Society (1988).	
	C75	MITCHELL, A.G. et al., "Bioreversible Protection for the Phospho Group: Bioactivation of the Di(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Phosphoesters of Methylphosphonate and Phosphonacetate," *J. Chem. Soc. Perkin Trans.* 1 , 2345-2353, Chemical Society, London (1992).	

Examiner Signature	Tom McK.	Date Considered	3/11/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant is to place a check mark here if English language translation is attached.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 9 of 12		
	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Description	T[1]
	C76	MITCHELL, J.R. et al., "Acetaminophen-Induced Hepatic Necrosis. IV. Protective Role of Glutathione," *J. Pharmacology and Experimental Therapeutics* 187(1), 211-217, The Williams & Wilkins Co. (1973).	
	C77	MITSUNOBU, O., "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products," *Synthesis* 1-28, Georg Thieme Verlag (1981).	
	C78	MOORE, M.M. et al., "Comparison of Mutagenicity Results for Nine Compounds Evaluated at the *hgprt* Locus in the Standard and Suspension CHO Assays," *Mutagenesis* 6, 77-85, Oxford University Press (1991).	
	C79	MURRAY, G.I. et al., "Cytochrome P450 CYP3A in Human Renal Cell Cancer," *British Journal of Cancer* 79, 1836-1842, Cancer Research Campaign (April 1999).	
	C80	MURRAY, G.I. et al., "Cytochrome P450 Expression is a Common Molecular Event in Soft Tissue Sarcomas," *J. Pathology* 171: 49-52, John Wiley & Sons, Ltd. (1993).	
	C81	NAGAMATSU, T. et al., "New Phosphorylating Agents for General Synthesis of Mixed Phosphate Esters," *Tetrahedron Lett.* 28(21), 2375-2378, Pergamon Journals Ltd. (1987).	
	C82	NAKAYAMA, K. et al., "A Highly Enantioselective Synthesis of Phosphate Triesters," *J. Am. Chem. Soc.* 112, 6936-6942, American Chemical Society (1990).	
	C83	OGG, M.S. et al., "A Reporter Gene Assay to Assess the Molecular Mechanisms of Xenobiotic-dependent Induction of the Human CYP3A4 Gene *in Vitro*," *Xenobiotica* 29(3), 269-279, Taylor & Francis Ltd. (March 1999).	
	C84	OHASHI, K. et al., "Synthesis of Phosphonosphingoglycolipid Found in Marine Snail *Turbo Cornutus*," *Tetrahedron Lett.* 29(10), 1189-1192, Pergamon Press plc. (1988).	
	C85	PETRAKIS, K.S. et al., "Palladium-Catalyzed Substitutions of Triflates Derived from Tyrosine-Containing Peptides and Simpler Hydroxyarenes Forming 4-(Diethoxyphosphinyl)phenylalanines and Diethyl Arylphosphonates," *J. Am. Chem. Soc.* 109, 2831-2833, American Chemical Society (1987).	
	C86	PETTIT, G.R. et al., "Antineoplastic Agents 322. Synthesis of Combretastatin A-4 Prodrugs," *Anti-Cancer Drug Design* 10, 299-309, Oxford University Press (1995).	
	C87	PITCHER, H.R., "Built-in Bypass," *Nature* 429, 39, Nature Publishing Group (May 2004).	
	C88	RAMU, K. et al., "Acrolein Mercapturates: Synthesis, Characterization, and Assessment of Their Role in the Bladder Toxicity of Cyclophosphamide," *Chem. Res. Toxicol.* 8, 515-524, American Chemical Society (1995).	

Examiner Signature		Date Considered	3/16/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant is to place a check mark here if English language translation is attached.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 10 of 12	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Description	T[1]
	C89	REDDY, M.R. et al., "Development of a Quantum Mechanics-Based Free-Energy Perturbation Method: Use in the Calculation of Relative Solvation Free Energies," *J. Am. Chem. Soc.* 126, 6224-6225, American Chemical Society (May 2004).	
	C90	REDMORE, D., "Phosphorus Derivatives of Nitrogen Heterocycles. 2. Pyridinephosphonic Acid Derivatives," *J. Org. Chem.* 35(12), 4114-4117, American Chemical Society (1970).	
	C91	REN, S. et al., "Inhibition of Human Aldehyde Dehydrogenase 1 by the 4-Hydroxycyclophosphamide Degradation Product Acrolein," *Drug Metabolism and Disposition* 27(1), 133-137, The American Society for Pharmacology and Experimental Therapeutics (January 1999).	
	C92	REN, S. et al., "Pharmacokinetics of Cyclophosphamide and its Metabolites in Bone Marrow Transplantation Patients," *Clinical Pharmacology and Therapeutics* 64(3), 289-301, Mosby, Inc. (September 1998).	
	C93	ROY, P. et al., "Development of a Substrate-Activity Based Approach to Identify the Major Human Liver P-450 Catalysts of Cyclophosphamide and Ifosfamide Activation Based on cDNA-Expressed Activities and Liver Microsomal P-450 Profiles," *Drug Metabolism and Disposition* 27(6), 655-666, The American Society for Pharmacology and Experimental Therapeutics (June 1999).	
	C94	SCHWARTZ, P.S. et al., "Cyclophosphamide Induces Caspase 9-Dependent Apoptosis in 9L Tumor Cells," *Molecular Pharmacology* 60(6), 1268-1279, The American Society for Pharmacology and Experimental Therapeutics (December 2001).	
	C95	SHIH, Y.-E. et al., "Studies on Potential Antitumor Agents (III). Synthesis of 4-Arylcyclophosphamides," *Heterocycles* 9 (9): 1277-1285, Sendai Institute of Heterocyclic Chemistry (1978).	
	C96	SHIH, Y.-E. et al., "Synthesis and Structure of 6-Phenylcyclophosphamides," *Heterocycles* 24(6), 1599-1603, Sendai Institute of Heterocyclic Chemistry (1986).	
	C97	SLADEK, N.E. et al., "Influence of Diuretics on Urinary General Base Catalytic Activity and Cyclophosphamide-Induced Bladder Toxicity," *Cancer Treatment Reports* 66(11), 1889-1900, U.S. National Cancer Institute (1982).	
	C98	SLADEK, N.E. et al., "Restoration of Sensitivity to Oxazaphosphorines by Inhibitors of Aldehyde Dehydrogenase Activity in Cultured Oxazaphosphorine-resistant L1210 and Cross-Linking Agent-resistant P388 Cell Lines," *Cancer Research* 45, 1549-1555, American Association for Cancer Research (1985).	
	C99	SPRINGATE, J. et al., "Toxicity of Ifosfamide and Its Metabolite Chloroacetaldehyde in Cultured Renal Tubule Cells," *In Vitro Cell Dev. Biol.-Animal* 35, 314-317, Society for In Vitro Biology (June 1999).	

Examiner Signature		Date Considered	3/11/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant is to place a check mark here if English language translation is attached.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 11 of 12	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Description	T[1]
	C100	SUMIDA, A. et al., "Quantitative Analysis of Constitutive and Inducible CYPs mRNA Expression in the HepG2 Cell Line Using Reverse Transcription-Competitive PCR," *Biochem. & Biophys. Res. Comm.* 267, 756-760, Academic Press (January 2000).	
	C101	TURNER, J.A., "A General Approach to the Synthesis of 1,6-,1,7-, and 1,8-Naphthyridines," *J. Org. Chem.* 55(15), 4744-4750, American Chemical Society (1990).	
	C102	VENOOK, A.P., "Treatment of Hepatocellular Carcinoma: Too Many Options?," *J. Clin. Oncol.* 12(6), 1323-1334, Lippincott Williams & Wilkins (1994).	
	C103	VO-QUANG, Y. et al., "(1-Amino-2-propenyl)phosphonic Acid, an Inhibitor of Alanine Racemase and D-Alanine:D-Alanine Ligase," *J. Med. Chem.* 29(4), 579-581, American Chemical Society (1986).	
	C104	WAGNER, A. et al., "Direct Conversion of Tetrahydropyranylated Alcohols to the Corresponding Bromides," *Tetrahedron Letters* 30(5), 557-558, Pergamon Press plc. (1989).	
	C105	WALLACE, E.M. et al., "Design and Synthesis of Potent, Selective Inhibitors of Endothelin-Converting Enzyme," *J. Med. Chem.* 41, 1513-1523, American Chemical Society (April 1998).	
	C106	WALSH, E.N. et al., "Phenoxymethylphosphonic Acids and Phosphonic Acid Ion-exchange Resins," *J. Am. Chem. Soc.* 78, 4455-4458, American Chemical Society (1956).	
	C107	WATANABE, Y. et al., "Dibenzyl Phosphorofluoridate, A New Phosphorylating Agent," *Tetrahedron Letters* 29(45), 5763-5764, Pergamon Press plc. (1988).	
	C108	WATKINS, P.B., "Noninvasive Tests of CYP3A Enzymes," *Pharmacogenetics* 4, 171-184, Chapman & Hall, London (1994).	
	C109	WEIBEL, M. et al., "Potentiating Effect of {2-[2-[(2-Amino-1,6-Dihydro-6-Oxo-9H-Purin-9-yl)Methyl]-Phenyl] Ethenyl}-Phosphonic Acid (MDL 74,428), A Potent Inhibitor of Purine Nucleoside Phosphorylase, on the Antiretroviral Activities of 2',3'-Dideoxyinosine Combined to Ribavirin in Mice," *Biochem. Pharmacol.* 48(2), 245-252, Elsevier Science Ltd. (1994).	
	C110	WEINHARDT, K. et al., "Synthesis and Antidepressant Profiles of Phenyl-Substituted 2-Amino- and 2-[(Alkoxycarbonyl)amino]-1,4,5,6-tetrahydropyrimidines," *J. Med Chem.* 28, 694-698, American Chemical Society (1985).	
	C111	WILEMAN, T. et al., "Receptor-Mediated Endocytosis," *Biochem. J.* 232: 1-14, Portland Press on behalf of the Biochemical Society, London (1985).	

Examiner Signature	Tom McKenzie	Date Considered	3/11/6C

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant is to place a check mark here if English language translation is attached.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 12 of 12	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Description	T[1]
	C112	YIP, K.F. et al., "Use of High-Performance Liquid Chromatography in the Preparation of Flavin Adenine Dinucleotide Analyte Conjugates," *J. of Chromatography* 326, 301-310, Elsevier Science Publishers B.V., Amsterdam (1985).	
	C113	YU, L.J. et al., "In vivo Modulation of Alternative Pathways of P-450-Catalyzed Cyclophosphamide Metabolism: Impact on Pharmacokinetics and Antitumor Activity," *J. Pharm. Exp. Ther.* 288(3), 928-937, The American Society for Pharmacology and Experimental Therapeutics (March 1999).	
	C114	YULE, S.M. et al., "The Effect of Fluconazole on Cyclophosphamide Metabolism in Children," *Drug Metabolism and Disposition* 27(3), 417-421, The American Society for Pharmacology and Experimental Therapeutics (March 1999).	

Examiner Signature	Date Considered	3/11/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant is to place a check mark here if English language translation is attached.

OIPE IAP34
JAN 25 2006
PATENT & TRADEMARK OFFICE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 1 of 1		
	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Description	T[1]
TCM	C115	DECHANT, K.L., et al., "Ifosfamide/Mesna. A Review of its Antineoplastic Activity, Pharmacokinetic Properties and Therapeutic Efficacy in Cancer," *Drugs* 42(3), 428-467 Adis International Limited (1991)	
TCM	C116	JAIN, M., et al., "Sulfonyl-Containing Aldophosphamide Analogues as Novel Anticancer Prodrugs Targeted against Cyclophosphamide-Resistant Tumor Cell Lines," *J. Med. Chem.* 47, 3843-3852 American Chemical Society (July 2004)	
TCM	C117	Prosecution history of Dang, Q., et al., U.S. Application No. 09/389,698, filed September 3, 1999, now patented as 6,489,476 B1	
	C118		
	C119		
	C120		
	C121		
	C122		
	C123		

Examiner Signature	Thomas McKenzie	Date Considered	1/16/06

489176_1.DOC

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant is to place a check mark here if English language translation is attached.

OIPE
JAN 31 2006
IAP13
PATENT & TRADEMARK OFFICE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 1 of 2		
	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant	Relevant Pages
	A14				
	A15				
	A16				
	A17				
	A18				
	A19				
	A20				
	A21				
	A22				
	A23				
	A24				
	A25				
	A26				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document (Cty code-number-kind)	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant	Relevant Pages	T[1]
TCM	B4	EP 0 072 987 A1	08-13-1982	Henkel Kommanditgesellschaft auf Aktien		
	B5					
	B6					
	B7					
	B8					
	B9					
	B10					
	B11					
	B12					
	B13					
	B14					

491819_1.DOC

Examiner Signature	Tom Mckenzie	Date Considered	3/11/05

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant is to place a check mark here if English language translation is attached.

OIPE
JAN 31 2006
IAP13
PATENT & TRADEMARK OFFICE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 2 of 2		
	Application No.	09/518,501
	Filing Date	03/03/2000
	First Named Inventor	Mark D. Erion
	Art Unit	1624
	Examiner Name	Thomas C. McKenzie
	Attorney Docket No.	2358.0010002 (MTI-013.US)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Description	T[1]
TCM	C118	Delphion English-language abstract of European Patent Publication No. 0 072 987 A1, 2 pages, accessed on October 20, 2005 at https://www.delphion.com/details?pn=EP00072987A1&s· FAMILY=1	
TCM	C119	Unverified English-language translation of European Patent Publication No. 0 072 987 A1, 13 pages	
	C120		
	C121		
	C122		
	C123		
	C124		
	C125		
	C126		
	C127		

Examiner Signature	Tom McKenzie	Date Considered	3/11/06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant is to place a check mark here if English language translation is attached.